Gossamer Reacquires Worldwide Seralutinib Rights, Plans September NDA After FDA Green Light
GOSS sits 72% above its 52-week low of $0.114 on elevated volume (14× avg).
Summary
Gossamer Bio reacquired worldwide rights to seralutinib from Chiesi for no upfront payment and announced plans to submit an NDA in September 2026 after favorable FDA feedback, transforming its regulatory and commercial outlook.
Key Events · Product Development and Regulatory · GOSS
-
Worldwide Seralutinib Rights Reacquired
Gossamer terminated its collaboration with Chiesi, regaining full global development and commercial rights to seralutinib. Chiesi pays Gossamer $5 million; Gossamer pays no upfront cash, only capped royalties and success-based milestones.
-
FDA Clears Path for NDA Submission
Following a Pre-NDA Type B meeting, the FDA characterized the PROSERA trial's statistical significance and treatment effect as review issues, not filing issues. Gossamer plans to submit the NDA in September 2026, with a potential approval decision in Q3 2027.
-
Preliminary Cash of $57 Million
As of June 30, 2026, Gossamer had approximately $57 million in cash, cash equivalents, and marketable securities, providing runway to reach the NDA submission milestone.
-
Reverse Stock Split Authorized
Stockholders approved a reverse stock split to support Nasdaq compliance and a more appropriate share structure; the company expects to effect it in or shortly after Q3 2026.
Analysis · GOSS · Life Sciences
By terminating its Chiesi collaboration, Gossamer regains full global control of seralutinib just ahead of a planned NDA submission in September 2026. The FDA has characterized the PROSERA trial's statistical significance and treatment effect as review issues rather than filing issues, clearing a path to submission. Under the new terms, Chiesi pays Gossamer $5 million and receives only capped royalties and milestones — no upfront cash from Gossamer. This reshapes the company's commercial economics and removes a major overhang, while the regulatory update materially de-risks the lead asset. With $57 million in preliminary cash, the company is positioned to reach the NDA milestone, though additional capital will likely be needed for commercialization.
At the time of this filing, GOSS was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $97.5M. The 52-week trading range was $0.11 to $3.87. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.